Tag Archives: McKesson Corp

McKesson says states seek $21 billion from drug distributors in opioid settlement

By Nate Raymond

(Reuters) – McKesson Corp said on Tuesday that it and two other major U.S. drug distributors could be expected pay up to $21 billion under a new proposal by state attorneys general to resolve lawsuits alleging they helped fuel the U.S. opioid crisis.

McKesson and rivals AmerisourceBergen Corp and Cardinal Health Inc last year proposed paying a combined $18 billion to resolve the roughly 3,200 lawsuits, with drugmaker Johnson & Johnson paying another $4 billion.

That proposal, part of a settlement framework negotiated with four state attorneys general, met resistance from lawyers for local governments and several states, leading to further talks. J&J on Oct. 13 said it would now contribute $5 billion.

McKesson in a quarterly report said that under the new $21 billion settlement framework proposed by attorneys general, the San Francisco-based company would pay about $8 billion over 18 years.

The company said the proposal was subject to further negotiations and that it “has not reached a point where settlement is probable.”

AmerisourceBergen declined to comment. Cardinal Health did not immediately respond to a request for comment.

The lawsuits, largely filed by states, counties and cities, seek to hold drug companies responsible for an opioid addiction epidemic that according to U.S. government data resulted in 450,000 overdose deaths from 1997 to 2018.

The lawsuits generally accuse drugmakers of deceptively marketing opioids and distributors of ignoring red flags indicating the prescription painkillers were being diverted for improper uses. They deny wrongdoing.

McKesson on Tuesday said in addition to the $21 billion, the proposed settlement also calls for the distributors to make changes to their programs to guard against the diversion of drugs for illicit purposes.

OxyContin maker Purdue Pharma and generic painkiller manufacturer Mallinckrodt Plc previously filed for bankruptcy protection in connection with their own multibillion-dollar proposals to resolve claims against them in the litigation.

(Reporting by Nate Raymond in Boston and Manas Mishra in Bengaluru; Editing by Peter Graff and Bill Berkrot)

J&J to contribute up to $5 billion to potential U.S. opioid settlement

(Reuters) – Johnson & Johnson on Tuesday said it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing the total amount it would pay to $5 billion.

The New Brunswick, New Jersey-based drugmaker said the additional money represented an increase to a proposed $4 billion settlement framework it negotiated with a group of state attorneys general that was announced last year.

That October 2019 proposal also called for the drug distributors McKesson Corp, Cardinal Health and AmerisourceBergen to pay a combined $18 billion, but the framework met resistance from some states and local governments.

Negotiations have been ongoing since then, and the dollar amounts have been shifting. J&J in a statement said the additional $1 billion it would pay reflected continued negotiations and said additional terms are being finalized.

Lawyers for the plaintiffs in the opioid litigation and representatives for several state attorneys general did not immediately respond to requests for comment.

More than 3,000 lawsuits have been filed nationally largely by states, counties and municipalities seeking to hold drug companies responsible for the U.S. opioid addiction epidemic.

The lawsuits generally accuse drugmakers including J&J of deceptively marketing opioids and distributors of ignoring red flags indicating the painkillers were being diverted for improper uses.

The companies including J&J deny wrongdoing. J&J is separately appealing a $465 million judgment the state of Oklahoma won against it in the first case to go to trial in the litigation.

(Reporting by Nate Raymond in Boston; Editing by Chris Reese)